SCHEMBL4329435

SCHEMBL4329435

C=CCN(N=Cc1ccc(-c2cc(Cl)ccc2Cl)o1)C(N)=S

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.58
HPGD P15428 8/20 0.58
ALDH1A1 P00352 8/20 0.58
KDM4E B2RXH2 7/20 0.58
LMNA P02545 6/20 0.58
MEN1 O00255 5/20 0.58
KMT2A Q03164 5/20 0.58
NPSR1 Q6W5P4 5/20 0.58
CYP1A2 P05177 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2C19 P33261 1/20 0.57
HTT P42858 2/20 0.55
NPC1 O15118 2/20 0.44
GAA P10253 2/20 0.44
MCL1 Q07820 2/20 0.44
RAB9A P51151 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329307 0.93 MAPT (0.48) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL4332906 0.84 PRMT5 (0.49) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL4341378 0.80 MAPT (0.48) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL4336312 0.79 ALDH1A1 (0.51) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL4453469 0.76 KDM4E (0.49) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL4336070 0.75 KDM4E (0.47) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL4336074 0.75 KDM4E (0.47) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL12417171 0.74 KDM4E (1.00) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL4344446 0.73 PTPN1 (0.51) MAPTHPGDALDH1A1KDM4ELMNA
SCHEMBL4344682 0.73 MAPT (0.42) MAPTHPGDALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885HPGD 1646/4885ALDH1A1 1459/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885HPGD 1495/4885ALDH1A1 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.